Final OS Results from the Phase 3 OPTIMAL Trial in EGFR-Positive NSCLC

Share this content:
Final results from OPTIMAL trial showed that patients with mutant type EGFR showed significant survival benefit when treated with erlotinib.
Final results from OPTIMAL trial showed that patients with mutant type EGFR showed significant survival benefit when treated with erlotinib.

Final results from the phase 3 OPTIMAL trial showed that patients with mutant type epidermal growth factor receptor (EGFR) showed significant overall survival (OS) benefit when treated with EGFR and tyrosine-kinase inhibitor (TKI) erlotinib.

The study suggested that erlotinib should be considered standard first-line treatment for EGFR mutant patients with non-small cell lung cancer (NSCLC), stated an article published online ahead of print in the Annals of Oncology

The OPTIMAL study compared the efficacy and tolerability of EGFR-TKI erlotinib versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced NSCLC.

Out of 165 randomized patients, 82 received erlotinib and 72 gemcitabine plus carboplatin. Final analyses were performed following the death of 70% of patients in the intent-to-treat population.

RELATED: BRAF Mutations in Non-Small Cell Lung Cancer

There were no significant between-group differences in the overall population, the exon 19 deletion subpopulation, or the exon 21 L858 mutation population.

Those who received sequential combination of EGFR-TKI with chemotherapy had significant improvement in OS compared with those who received either monotherapy with EGFR-TKI or chemotherapy (29.7 months, 20.7, and 11.2, respectively).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs